

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|---------------------|
| Application Number | 10/583,927 |
| Filing Date | December 23, 2004 |
| First Named Inventor | Sek Chung Fung |
| Art Unit | 1643 |
| Examiner Name | Stephen L. Rawlings |
| Attorney Docket No. | 12279-187-999 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Document Number – Kind Code | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|----------|-----------------------------|-----------------------------|---|---|
| | A21 | US 2010-0266494 A1 | 10/21/2010 | Fung et al. | |
| | A22 | US 2003-235555 A1 | 12/25/2003 | Shealey et al. | |
| | A23 | 5652123 | 7/27/1997 | Caput et al. | |
| | A24 | 5717072 | 2//10/1998 | Mosley et al. | |
| | A25 | 5965709 | 10/12/1999 | Presta et al. | |
| | A26 | 5994514 | 11/20/1999 | Jardieu et al. | |
| | A27 | 6037453 | 3/14/2000 | Jardieu et al. | |
| | A28 | 6,143,871 | 11/07/2000 | Bonnefoy et al. | |
| | A29 | 6299875 | 10/09/2001 | Caplan et al. | |
| | A30 | 6329509 | 12/11/2001 | Jardieu et al. | |
| | A31 | 6576232 B1 | 6/10/2003 | Debinski et al. | |
| | A32 | 6664227 | 12/16/2003 | Wynn et al. | |
| | A33 | 6743604 | 6/01/2004 | Bonnefoy et al. | |
| | A34 | 7,615,213 B2 | 11/10/2009 | Kasaian et al. | |
| | A35 | 7,674,459 B2 | 03/09/2010 | Fung et al. | |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Foreign Patent Document Country Code, Number, Kind Code (if known) | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|----------|--|-----------------------------|---|---|---|
| | B24 | EP 0876482 (B1) | 03/19/2003 | Sanofi SA [FR] (in French with English Abstract) | | |
| | B25 | EP 1141286 (B1) | 10/18/2006 | Genetics Inst [US] and Univ Johns Hopkins [US] | | |
| | B26 | JP 2007-161724 (corresponding to WO 2005/062967) | 06/28/2007 | Tanox Inc. (in Japanese with English Abstract) | | |
| | B27 | JP 2008-500024 (corresponding to WO 2005/062967) | 01/10/2008 | Tanox Inc. (in Japanese with English Abstract) | | |
| | B28 | WO 97/20926 (A1) | 06/12/1997 | Sanofi SA [FR] et al. (in French with English Abstract) | | |
| | B29 | WO 00/23410 A2 | 4/27/2000 | Bayer AG | | |

NYI-4245742

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|---------------------|
| Application Number | 10/583,927 |
| Filing Date | December 23, 2004 |
| First Named Inventor | Sek Chung Fung |
| Art Unit | 1643 |
| Examiner Name | Stephen L. Rawlings |
| Attorney Docket No. | 12279-187-999 |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Foreign Patent Document Country Code, Number, Kind Code (if known) | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|----------|--|-----------------------------|---|---|---|
| | B30 | WO 00/444074 A2 | 8/03/2000 | Amgen Canada | | |
| | B31 | WO 01/34645 A2 | 5/17/2001 | The Govt of the USA | | |
| | B32 | WO 01/92514 A1 | 6/12/2001 | Shanghai Biowindow Gene Development Inc. | | |
| | B33 | WO 03/035847 A2 | 5/01/2003 | Centocor, Inc. | | |
| | B34 | WO 03/086451 A1 | 10/23/2003 | Centocor, Inc. | | |
| | B35 | WO 2003/040164 A2 | 5/15/2003 | Cytos Biotechnology AG [CH] | | |
| | B36 | WO 2004/001655 A1 | 12/31/2003 | Office of Technology Transfer, Dept. of Health and Human Services representing Government of United States of America | | |
| | B37 | WO 2004/019974 A2 | 3/11/2004 | Glaxo Group Ltd [GB] | | |
| | B38 | WO 2004/019979 A2 | 3/11/2004 | Glaxo Group Ltd [GB] | | |
| | B39 | WO 2005/121177 A2 | 12/22/2005 | Wyeth | | |
| | B40 | WO 2005/123126 A2 | 12/29/2005 | Wyeth | | |
| | B41 | WO 2007/036745 (A2,A3) | 04/05/2007 | Cambridge Antibody Tech [GB] et al. | | |
| | B42 | WO 2007/045477 (A2, A3) | 04/26/2007 | Novartis AG [CH] ; Novartis Pharma GMBH [AT] | | |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|---|
| | C72 | "Monoclonal Anti-Human IL 13 Antibody," R&D Systems, Inc. Catalog [on-line], October 2002 [retrieved on October 14, 2002], Retrieved from the Internet:< URL: http://www.rndsystems.com/asp/c_search.asp?ucategory=3&factors=IL.%2D13 >. | |
| | C73 | AHLERS et al., 2002, "A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L." Proc Natl Acad Sci U S A; 99(20):13020-5 | |
| | C74 | AKBARI et al., 2003, "Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity." Nat Med. 9(5):582-8 | |
| | C75 | ALBERTS et al., 1994, "An antibody molecule is composed of two identical light chains and two identical heavy chains," Molecular Biology of the Cell, Third Edition, Garland Publishing, Inc., New York, pp. 1208-1209 | |
| | C76 | AMRAD CORPORATION, Ltd. "IL-13 Receptor Antibody Project." August 17, 2005 | |
| | C77 | ARIMA et al., 2002, "Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma." J Allergy Clin Immunol. 109(6):980-7 | |
| | C78 | ARIMA et al., 2005, "Characterization of the interaction between interleukin-13 and interleukin-13 receptors". J. Biol. Chem. Vol. 280(26):24915-24922 | |

NYI-4245742

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|---------------------|
| Application Number | 10/583,927 |
| Filing Date | December 23, 2004 |
| First Named Inventor | Sek Chung Fung |
| Art Unit | 1643 |
| Examiner Name | Stephen L. Rawlings |
| Attorney Docket No. | 12279-187-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|---|
| | C79 | ASTHMA AND ALLERGY FOUNDATION OF AMERICA and The National Pharmaceutical Council, "A Closer Look at Asthma" A joint publication of AAFA and NPC, pp. 1-6 | |
| | C80 | BLEASE et al., 2001, "Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma," J. Immunol., Vol. 165:5219-5224 | |
| | C81 | BREWER et al., 2004, "Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis," J. Inorg. Biochem. 98(12):2160-7 | |
| | C82 | BROWN et al., 1989, "A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes." J. Immunol. 142(2):679-87 | |
| | C83 | CARRINGTON, B., "BIAcore analysis of hIL-13Rα2 binding/blocking to hIL-13 pre-bound to antibody JES10-5A2 or antibody 213," June 7, 2007, UCB Celltech, pp. 1-3 | |
| | C84 | COHN et al. 1998, "Cutting Edge: IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells," J. Immunol. Vol.161:3813-3816 | |
| | C85 | COHN et al., 1997, "Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production." J. Exp. Med. Vol.186(10):1737-1747 | |
| | C86 | DANIELS et al., 2004, "Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis." J. Clin. Invest. 114(9):1308-16 | |
| | C87 | DE SWART et al., 2002, "Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76(22):11561-9 | |
| | C88 | Dorland's Illustrated Medical Dictionary, 28 th ed., 1994, p. 151 | |
| | C89 | ENCYCLOPEDIA BRITANNICA'S GUIDE TO THE NOBEL PRIZES, 2007, "Immune system disorders," [on-line], June 27, 2007 [retrieved on June 27, 2007], pp. 1-4, Retrieved from the Internet:< URL: http://www.britannica.com/nobelprize/article-215507 > | |
| | C90 | HASEGAWA et al., 2003, "Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma." Dermatology. 207(2):141-7 | |
| | C91 | HELLER et al., 2002, "Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells." Immunity. 17(5):629-38 | |
| | C92 | HELLER et al., 2005, "Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution." Gastroenterology. 129(2):550-64 | |
| | C93 | HERSHEY GK., 2003, "IL-13 receptors and signaling pathways: an evolving web." J. Allergy Clin. Immunol. 111(4):677-90 | |
| | C94 | International Search Report mailed August 17, 2006 for PCT International Patent Application No. PCT/US2004/43501 | |
| | C95 | International Search Report mailed August 2, 2005 for PCT International Patent Application No. PCT/US2004/43541 | |
| | C96 | JAKUBZICK et al., 2003, "Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells." J Immunol. 171(5):2684-93 | |
| | C97 | JANEWAY et al., Chapter 11, 3 rd ed. of Immunobiology, 1997 | |
| | C98 | JANEWAY et al., Chapter 12, 3 rd ed. of Immunobiology, 1997 | |
| | C99 | JANEWAY et al., Section 9:18, 3 rd ed. of Immunobiology, 1997 | |
| | C100 | KAWAKAMI et al., 2002, "Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts." Mol Cancer Ther. 1(12):999-1007 | |
| | C101 | KEANE et al., 1999, "IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis." J Immunol. 163(10):5686-92 | |

NYI-4245742

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|---------------------|
| Application Number | 10/583,927 |
| Filing Date | December 23, 2004 |
| First Named Inventor | Sek Chung Fung |
| Art Unit | 1643 |
| Examiner Name | Stephen L. Rawlings |
| Attorney Docket No. | 12279-187-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|---|---|
| | C102 | KEANE et al., 1999, "Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis." J Immunol. 162(9):5511-8 | |
| | C103 | KIM et al., 2002, "IL-13-induced Clara cell secretory protein expression in airway epithelium: role of EGFR signaling pathway." Am. J. Physiol. Lung Cell Mol. Physiol 283:L67-L75 | |
| | C104 | KUPERMAN et al., 2002, "Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma." Nat. Med. 8(8):885-9 (copy of advanced online publication available) | |
| | C105 | LAPORTE et al., 2008, "Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system," Cell. Vol. 132(2):259-272 (HHMI Author Manuscript) | |
| | C106 | LAUDER & MCKENZIE, 2001, "Measurement of Interleukin-13," Current Protocols in Immunology, Unit 6.18, Supplement 46, 6.18.1-6.18.6, John Wiley & Sons, Inc., New York | |
| | C107 | LEE et al., 2001, "Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma." J. Asthma. 38(8):665-71 | |
| | C108 | LIU et al., 2004, "Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6." J. Immunol. 173(5):3425-31 | |
| | C109 | LUKACS et al., 2001, "Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms." J. Immunol. 167(2):1060-5 | |
| | C110 | MADHANKUMAR et al., 2002, "Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine." J Biol Chem. 277(45):43194-205 | |
| | C111 | MATSUSHITA et al., 2004, "Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma." Int. Arch. Allergy Immunol. 135(4):348-56 | |
| | C112 | MERCK MANUAL - ONLINE MEDICAL DICTIONARY, "Hyperimmunoglobulinemia E Syndrome" [online], July 7, 2007 [Retrieved on July 7, 2007], Retrieved from the Internet:< URL: http://www.merck.com/mmhe/sec16/ch184k.html >, pp. 1-2, | |
| | C113 | MILOUX et al., 1997, "Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex." FEBS Lett. 401(2-3):163-6 | |
| | C114 | MUELLER et al., 2002, "Structure, binding, and antagonists in the IL-4/IL-13 receptor system," Biochimica et Biophysica Acta. Vol. 1592(3):237-250 | |
| | C115 | OKUMA et al., 2004, "C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases." J. Pathol. 204(5):594-604 | |
| | C116 | OXFORD CONCISE MEDICAL DICTIONARY, "Atopy," Fourth Edition 1994, Oxford University Press, Great Britain, pp. 54-55 | |
| | C117 | PEEBLES et al., 2001, "Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges." J Infect Dis. 184(11):1374-9 | |
| | C118 | REECK et al., 1987, "Homology" In Proteins And Nucleic Acids: A Terminology Muddle And A Way Out Of It. Cell. 50(5):667 | |
| | C119 | ROBERGE et al., 1998, "Treatment of uveitis with recombinant human interleukin-13." Br J Ophthalmol. 82(10):1195-8 | |
| | C120 | RUDIKOFF et al., 1982, "Single amino acid substitution altering antigen-binding specificity." Proc. Nat'l Acad. Sci. U.S.A., Vol. 79(6): 1979-1983. | |
| | C121 | SCHACKER et al, 2002, "Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis." J. Clin. Invest. 110(8):1133-9 | |
| | C122 | SINGER et al., 1998, "Gens and Genoms", Moscow, Mir. 1988. Vol. 1, p. 63 (In Russian with English translation) | T |
| | C123 | TABER'S CYCLOPEDIA MEDICAL DICTIONARY, "Atopy," 18th Edition. F.A. Davis Company, Philadelphia, 1993, p. 170 | |

NYI-4245742

| | |
|--|------------------------|
| EXAMINER SIGNATURE | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|---------------------|
| Application Number | 10/583,927 |
| Filing Date | December 23, 2004 |
| First Named Inventor | Sek Chung Fung |
| Art Unit | 1643 |
| Examiner Name | Stephen L. Rawlings |
| Attorney Docket No. | 12279-187-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|---|
| | C124 | TEPLYAKOV et al., 2009, "Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607," J. Mol. Biol. Vol. 389(1):115-123 | |
| | C125 | TEPLYAKOV et al., 2010, "On the domain pairing in chimeric antibodies," Mol. Immunol. Vol. 47(14):2422-2426 | |
| | C126 | THOMPSON et al., 1999, "Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors," J. Biol. Chem., Vol. 274(42):29944-29950 | |
| | C127 | TSARBOPOULOS et al., 2000, "Mass spectrometric mapping of disulfide bonds in recombinant human interleukin-13," J. Mass. Spectrom., Vol. 35(3):446-453 | |
| | C128 | VITA et al., 1995, "Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types," J. Biol. Chem. 270(8):3512-3517 | |
| | C129 | WARDEMANN et al., 2003, "Predominant autoantibody production by early human B cell precursors," Science Vol. 301(5638):1374-1377 | |
| | C130 | WIKIPEDIA entry for "Hypersensitivity" [on-line], [Retrieved on July 2, 2007], pp. 1-4, Retrieved from the Internet:< URL: http://en.wikipedia.org/wiki/Hypersensitivity > | |
| | C131 | WILLS-KARP M., 2004, " Interleukin-13 in asthma pathogenesis." Curr. Allergy Asthma Rep. 4(2):123-31. | |
| | C132 | ZUEGG et al., 2001, "Structural model of human IL-13 defines the spatial interactions with the IL-13 α /IL-4 α receptor," Immunol. Cell Biol. Vol. 79(4):332-339 | |

NYI-4245742

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.